Treatment of Chronic Hepatitis due to Hepatitis C Virus (CH-C) in India: A Randomized Controlled Trial Comparing Daily Interferon-alfa-2b and Ribavirin with Daily Interferon-alfa-2b and Glycyrrhizin—A Multicenter Study

Seef, 2002, Natural history of chronic hepatitis C, Hepatology, 36, S35, 10.1002/hep.1840360706 Panigrahi, 1997, Magnitude of hepatitis C virus infection in India: prevalence in healthy blood donors, acute and chronic liver diseases, J Med Virol, 51, 167, 10.1002/(SICI)1096-9071(199703)51:3<167::AID-JMV5>3.0.CO;2-4 Acharya, 2006, Viral hepatitis in India, Natl Med J India, 19, 203 Wasley, 2000, Epidemiology of hepatitis C: geographic differences and temporal trends, Semin Liver Dis, 20, 1, 10.1055/s-2000-9506 Panigrahi, 1996, Genotype determination of hepatitis C virus from northern India: identification of a new subtype, J Med Virol, 48, 191, 10.1002/(SICI)1096-9071(199602)48:2<191::AID-JMV12>3.0.CO;2-I Hazari, 2004, Treatment of hepatitis C virus infection in patients of northern India, J Gastroenterol Hepatol, 19, 1058, 10.1111/j.1440-1746.2004.03405.x Amarapurkar, 2001, Prevalence of hepatitis C genotypes in Indian patients and their clinical significance, J Assoc Physic India, 49, 983 Valliammai, 1995, Diversity of genotypes of hepatitis C virus in southern India, J Gen Virol, 76, 711, 10.1099/0022-1317-76-3-711 Raghuraman, 2003, Distribution of the different genotypes of HCV among patients attending a tertiary care hospital in south India, J Clin Virol, 26, 61, 10.1016/S1386-6532(02)00025-2 Khuroo, 1993, Hepatitis C virus antibodies in acute and chronic liver disease in India, J Hepatol, 17, 175, 10.1016/S0168-8278(05)80034-0 Strader, 2004, American Association for the Study of Liver Diseases: diagnosis, management, and treatment of hepatitis C, Hepatology, 39, 1147, 10.1002/hep.20119 Abe, 1982, Interferon induction by glycyrrhizin and glycyrrhetinic acid in mice, Microbiol Immunol, 26, 535, 10.1111/j.1348-0421.1982.tb00207.x Shiki, 1992, Effect of glycyrrhizin on lysis of hepatocyte membranes induced by anti-liver cell membrane antibody, J Gastroenterol Hepatol, 7, 12, 10.1111/j.1440-1746.1992.tb00927.x Nagai, 1992, Attenuation of dysfunction in the ischemia-reperfused liver by glycyrrhizin, Jpn J Pharmacol, 58, 209, 10.1254/jjp.58.209 Shinada, 1986, Enhancement of interferon-gamma production in glycyrrhizin-treated human peripheral lymphocytes in response to concanavalin A and to surface antigen of hepatitis B virus, Proc Soc Exp Biol Med, 181, 205, 10.3181/00379727-181-42241 Fujisawa, 1973, Therapeutic approach to chronic active hepatitis with Glycyrrhizin, Asian Med J, 23, 745 Suzuki, 1983, Effects of glycyrrhizin on biological tests in patients with chronic hepatitis: a double-blind trial, Asian Med J, 26, 423 Yasuda, 1991, Effects of high dose therapy with stronger neo-minophagen C (SNMC) on hepatic histography in non-A, non-B chronic active hepatitis, 205 Pompei, 1979, Glycyrrhizic acid inhibits virus growth and inactivates virus particles, Nature, 281, 689, 10.1038/281689a0 Acharya, 2007, Hepatitis E virus (HEV) infection in patients with cirrhosis is associated with rapid decompensation and death, J Hepatol, 46, 387, 10.1016/j.jhep.2006.09.016 Desmet, 1994, Classification of chronic hepatitis: diagnosis, grading and staging, Hepatology, 19, 1513, 10.1002/hep.1840190629 Vikram, 2003, Correlations of C-reactive protein levels with anthropometric profile, percentage of body fat and lipids in healthy adolescents and young adults in urban North India, Atherosclerosis, 168, 305, 10.1016/S0021-9150(03)00096-0 Bukh, 1992, Importance of primer selection for the detection of hepatitis C virus RNA with the polymerase chain reaction assay, Proc Natl Acad Sci USA, 89, 187, 10.1073/pnas.89.1.187 Lole, 2003, Comparison of hepatitis C virus genotyping by 5′ noncoding region- and core-based reverse transcriptase PCR assay with sequencing and use of the assay for determining subtype distribution in India, J Clin Microbiol, 41, 5240, 10.1128/JCM.41.11.5240-5244.2003 Chowdhury, 2003, Hepatitis C virus infection in general population: a community-based study in West Bengal, India, Hepatology, 37, 802, 10.1053/jhep.2003.50157 Manns, 2001, Peginterferon alfa-2b plus ribavirin compared with interferon alfa 2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial, Lancet, 358, 958, 10.1016/S0140-6736(01)06102-5 2002, National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002), Gastroenterology, 123, 2082, 10.1053/gast.2002.1232082 Fried, 2002, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection, N Eng J Med, 347, 975, 10.1056/NEJMoa020047 Tohra, 2011, Prediction of SVR to combination therapy with pegylated interferon alfa and ribavirin in patients with genotype 3 chronic hepatitis C, Dig Dis Sci, 56, 2449, 10.1007/s10620-011-1770-3 Lindsay, 2001, A randomized, double blind trial comparing pegylated interferon alfa-2b to interferon alfa 2b as initial treatment for chronic hepatitis C, Hepatology, 34, 395, 10.1053/jhep.2001.26371 Rodriguez-Torres, 2009, Peginterferon alfa-2a and ribavirin in Latino and non-Latino whites with hepatitis C, N Eng J Med, 360, 257, 10.1056/NEJMoa0805062 Hepburn, 2004, Differences in treatment outcomes for hepatitis C among ethnic group, Am J Med, 117, 163, 10.1016/j.amjmed.2004.02.043 Manns MP, Zeuzem S, Sood A, et al. Reduced dose and duration of pegylated interferon alpha 2b and weight based ribavirin in European and Asian genotype 2 and 3 chronic hepatitis C patients (REDD2/REDD3 trial). Presented in 44th Annual EASL Conference, Copenhagen, April 26, 2009.